Related Experiment Videos
[Advancements in PSA-based screening for prostate cancer]
1Department of Urology, Gunma University Graduate School of Medicine Maebashi, 371-8511.
Rinsho Byori. the Japanese Journal of Clinical Pathology
|September 4, 2004
Summary
Optimizing prostate cancer screening involves age-specific prostate-specific antigen (PSA) cut-offs and tailored biopsy strategies. Future systems aim to reduce mortality and costs effectively.
Area of Science:
- Urology
- Oncology
- Public Health
Context:
- Prostate cancer is a leading cause of cancer death in Western countries, necessitating effective screening strategies.
- Current prostate-specific antigen (PSA) screening for asymptomatic men remains controversial, with ongoing trials to clarify its benefits.
- Developing an optimal, cost-effective screening system is crucial for managing prostate cancer burden.
Purpose:
- To evaluate the effectiveness of an optimized screening system for prostate cancer.
- To determine age-specific cut-off values for PSA and refine re-screening protocols.
- To assess the utility of PSA density adjusted by transition zone volume (PSATZD) and free/total PSA ratio (%f-PSA) in biopsy selection.
Summary:
- The PSA test is the preferred initial screening method, with age-adjusted cut-offs recommended.
- Re-screening decisions should consider baseline PSA and digital rectal examination findings.
- PSATZD and %f-PSA may aid in selecting patients for biopsy, with optimal cut-offs requiring further confirmation and age-adjustment. Biopsy core number should be adjusted for prostate volume and patient age.
Impact:
- This research aims to improve prostate cancer detection rates while minimizing costs and unnecessary procedures.
- Refined screening protocols can lead to earlier diagnosis of clinically significant prostate cancer.
- Future advancements in screening and minimally invasive treatments may enhance the utility of prostate cancer screening, particularly for elderly males.